Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915444 · ClinicalTrials.gov registry record · Phase 2
Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
A Phase 2 study of Pancreatic Ductal Adenocarcinoma, sponsored by HonorHealth Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 4
- Study locations
NCT03915444: Active Phase 2 study of Pancreatic Ductal Adenocarcinoma, sponsored by HonorHealth Research Institute.
NCT03915444 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by HonorHealth Research Institute. The registered enrollment target is 42 participants, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03915444, a Phase 2 study of Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by HonorHealth Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Primary Outcome
Evaluate the 12-month OS rate in patients with metastatic Pancreatic ductal adenocarcinoma (PDA) treated with nab-paclitaxel plus cisplatin plus gemcitabine
Conditions Studied
Interventions
- DRUG nab-Paclitaxel + Cisplatin + Gemcitabine
Study Locations (4)
Arizona
- HonorHealth Research Institute - Scottsdale
Florida
- University of Miami - Miami
Louisiana
- Ochsner Clinic Foundation - New Orleans
Wisconsin
- Froedtert & Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2023-07-31 |
| Phase | Phase 2 |
What the registry record for NCT03915444 still lists
NCT03915444 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which nab-Paclitaxel + Cisplatin + Gemcitabine is the first listed.
NCT03915444 reports a single indexed study location in Arizona, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT03915444 about?
NCT03915444 is a clinical study titled "Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma". This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
What is the current status of trial NCT03915444?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2019-07-15. Estimated completion is 2023-07-31.
What conditions does trial NCT03915444 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT03915444?
The interventions under investigation include: nab-Paclitaxel + Cisplatin + Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT03915444?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03915444 being conducted?
This trial has 4 study locations across Arizona, Florida, Louisiana, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03915444's enrollment target sits among peer trials
42 60th of 84 higher than 25 of 84 other Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
-
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI